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University of Pennsylvania, Philadelphia, PennsylvaniaABSTRACT The microsecond folding and unfolding kinetics of ovine prion proteins (ovPrP) were measured under various
solution conditions. A fragment comprising residues 94–233 of the full-length ovPrP was studied for four variants with differing
susceptibilities to classical scrapie in sheep. The observed biexponential unfolding kinetics of ovPrP provides evidence for an
intermediate species. However, in contrast to previous results for human PrP, there is no evidence for an intermediate under
refolding conditions. Global analysis of the kinetic data, based on a sequential three-state mechanism, quantitatively accounts
for all folding and unfolding data as a function of denaturant concentration. The simulations predict that an intermediate accu-
mulates under both folding and unfolding conditions, but is observable only in unfolding experiments because the intermediate is
optically indistinguishable from the native state. The relative population of intermediates in two ovPrP variants, both transiently
and under destabilizing equilibrium conditions, correlates with their propensities for classical scrapie. The variant susceptible to
classical scrapie has a larger population of the intermediate state than the resistant variant. Thus, the susceptible variant should
be favored to undergo the PrPC to PrPSc conversion and oligomerization.INTRODUCTIONPrion diseases are a class of neurodegenerative diseases that
includes scrapie in sheep and goats, bovine spongiform
encephalopathy in cattle (mad cow disease), as well as fatal
familial insomnia, Gerstmann-Straussler-Scheinker syn-
drome, and Creutzfeldt-Jakob disease in humans. According
to the prevailing hypothesis (1), prion diseases result from
the misfolding of a naturally occurring prion protein (PrP)
from its normal cellular form (PrPC) to a virulent scrapie
form (PrPSc). This abnormal isoform is able to catalyze
the conversion of PrPC to itself, and has been associated
with prion infectivity (1–3). Although the cause of neuronal
death in prion diseases remains unclear, all pathogenesis
models involve the structural conversion of PrPC to PrPSc
(4). PrPC is a copper-binding (5,6), cell-surface glycoprotein
(7) composed of an unstructured N-terminal domain and
a globular C-terminal domain (residues 126–233) of known
structure, comprising three a-helices, a short two-stranded
antiparallel b-sheet, and a disulfide bond (Cys182-Cys217,
which corresponds to Cys179-Cys214 in human PrP) linking
helices 2 and 3 (8–11) (Fig. 1). Relatively little is known
about the structure of PrPSc, except that it appears to have
significantly more b-sheet and slightly less a-helix (17–
30% a-helix; 43–54% b-sheet) compared to PrPC (42%
a-helix; 3% b-sheet) (12–14).
Polymorphisms of ovine PrP (ovPrP) have been associ-
ated with differing susceptibility to classical scrapie, partic-Submitted March 8, 2011, and accepted for publication July 18, 2011.
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0006-3495/11/09/1221/10 $2.00ularly at positions 136 (A/V), 154 (H/R), and 171 (Q/R).
The A136R154R171 (ARR) and A136H154Q171 (AHQ) alleles
confer resistance, whereas the V136R154Q171 (VRQ) and
A136R154Q171 (ARQ) genotypes are correlated with suscep-
tibility (15–18). Several factors, alone or in combination,
might account for this genetic modulation. Variations in
conformations and glycosylation patterns between allelic
variants have been suggested to modulate scrapie suscepti-
bility by altering solvent accessibility (19,20). PrPC variants
susceptible to classical scrapie have been shown to have
longer cellular half-lives (21) and higher plasma concentra-
tions (22), when compared to resistant variants, which might
give them more opportunities to convert and oligomerize.
Finally, the propensity for the PrPC-to-PrPSc conversion,
both in vitro and ex vivo, has also been suggested to corre-
late with susceptibility to classical scrapie (23,24). The
PrPC-to-PrPSc conversion efficiencies of ovPrP allelic vari-
ants depend on the exogenously introduced PrPSc strain.
However, the ARR variant exhibits the lowest conversion
efficiency regardless of the strain introduced.
Because this structural conversion requires at least partial
unfolding, it would be plausible to hypothesize that more
susceptible variants are less stable structurally (25). How-
ever, exactly the opposite is observed for classical scrapie:
variants with lower structural stability (as measured by the
free energy difference DGNU between the folded and
unfolded states) are less prone to the disease than those
with higher structural stability (26,27). Differences in in vivo
clearance have been proposed to explain this inverse corre-
lation (21); nevertheless, it cannot explain the higher in vitro
conversion propensities displayed by susceptible variants
(23). To account for this apparent paradox, we hypothesizeddoi: 10.1016/j.bpj.2011.07.024
FIGURE 1 Ribbon representation of the structure of ovPrP (residue 126–
233), based on a crystal structure (pdb ID 1UW3 (11)). The structure
comprises three a-helices (H1–H3), a short antiparallel b-sheet (B), and
a disulfide bridge (SS) linking H2 and H3. The residues involved in genetic
modulation in sheep scrapie and the engineered fluorescence probe (Trp-
221) are labeled.
1222 Chen et al.that polymorphisms affect the susceptibility by modulating
the population and structural properties of the ovPrPSc
precursor, which we took to be a folding intermediate.
This hypothesis led us to examine two subquestions:
First, do the folding and unfolding of ovPrP proceed through
an intermediate? Second, if so, is this folding intermediate
the precursor of ovPrPSc? A folding intermediate has been
linked to human familial prion diseases (28,29). However,
it is unclear whether such a PrP intermediate exists in other
species, and if so, whether the properties of this intermediate
and its role in genetic modulation are consistent across
species.
To study these questions and the folding of ovPrP in
general, we measured the microsecond folding and unfold-
ing kinetics of these allelic variants under various solution
conditions, including two temperatures (5 and 15C), two
pH values (5 and 7), and two denaturants, guanidine hydro-
chloride (GuHCl) and urea. The unfolding kinetics of ovPrP
exhibited two exponentials at pH 7, which indicates the
presence of at least one intermediate species besides the
native (N) and unfolded (U) species. The most plausible
kinetic model seems to be N4 I4 U in which the native
species N unfolds quickly to an intermediate I before
unfolding completely to U. Adopting this kinetic model,
we found that the population of I in the variants correlateBiophysical Journal 101(5) 1221–1230with their differing propensities toward classical scrapie.
The variant with higher classical scrapie propensity is char-
acterized by a higher population in I. Our findings support
the hypothesis that the formation of this partially unfolded
intermediate is an early step in the formation of ovPrPSc.MATERIALS AND METHODS
Protein preparation and purification
Unless stated otherwise, reagents and buffers were purchased from Sigma-
Aldrich (St. Louis, MO) in the highest grade available. The plasmid encod-
ing ovPrP94-233, ARQ allele with an N-terminal (His)6 tag was a generous
gift from Dr. P. M. Bayley (11). Based on this parental plasmid, ARR, AHQ,
and VRQ variants were constructed by site-directed mutagenesis using
QuikChange kit (Stratagene, Santa Clara, CA) and appropriate primers
(see the Supporting Material, Table S1). To introduce a fluorescence probe,
all polymorphic variants contained additional W102F and Y221W muta-
tions. All sequences were confirmed by DNA sequencing. Ovine numbering
is used throughout this article unless specified otherwise.
These plasmids were transformed into competent Escherichia coli BL21
(DE3) cells and expressed by isopropyl b-D-1-thiogalactopyranoside
induction. Because the expressed ovPrP variants accumulate in inclusion
bodies, 8 M urea was used to solubilize the proteins. Purification was
carried out by metal-affinity chromatography using nickel-nitrilotriacetic
acid resin (Qiagen, Valencia, CA). Protein concentration was determined
by the optical density at 280 nm using an extinction coefficient predicted
from the amino-acid composition, e.g., 23,505 M1cm1 for the wild-
type protein (30). The identity of the purified protein was confirmed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blot-
ting, and mass spectrometry.Continuous-flow measurements
For kinetic measurements on the submillisecond timescale, we used a
modified version of the continuous-flow capillary mixing instrument
described by Shastry et al. (31), including an ultraviolet (UV)-enhanced
charge-coupled device camera system (Alta U47-UV, Apogee Instruments,
Roseville, CA). The excitation wavelength was 297 nm, and tryptophan
fluorescence emission was collected using a 324 nm cut-on filter (Edmund
Optics, Barrington, NJ). For most experiments, mixing was carried out at
15C at a flow rate of 1.8 ml/s, with a final protein concentration of ~11 mM.
The refolding (resp. unfolding) reactions were initiated by diluting the
unfolded (resp. native) protein at 1:5 ratio into the refolding (resp. unfold-
ing) buffer containing desired denaturant concentrations that promote
refolding (resp. unfolding). The buffer consisted of GuHCl or urea in either
50 mM sodium acetate, pH 5 or 50 mM imidazole, pH 7. The concentration
of denaturants was determined from its refractive index.
The instrumental dead time of the continuous-flowmixer was determined
by measuring the reaction of N-acetyl-L-tryptophan (NAT) with N-bromo-
succinimide (NBS) at several concentrations of NBS. With appropriate
amounts of glycerol included to match the viscosity of denaturants in our
refolding experiments (Fig. S1), the dead time of the capillary mixer was
39 5 4 ms. At higher viscosity, matching that of the final GuHCl concen-
tration used for unfolding, the dead time was slightly longer (425 4 ms).
The use of glycerol to simulate denaturant solutions was necessary because
NBS is unstable in concentrated solutions of GuHCl or urea. We recently
found that N-acetyl-L-tryptophan-amide, which has traditionally been
used for testing mixer performance (31,32), shows nonexponential
kinetics because NBS can react not only with the indole ring, but also
with the C-terminal amide protecting group (M. Xu and H. Roder, unpub-
lished data). In contrast, NAT lacks a reactive amide and shows simple
pseudo first-order (exponential) kinetics in the presence of a molar excess
of NBS.
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The fluorescence signal was fit to a sum of exponentials using the least-
squares algorithm as implemented in IGOR Pro software (Wavemetrics).
In every case, the residuals were examined to confirm the absence of
systematic errors. Under strongly denaturing conditions, two exponentials
were necessary to fit the kinetic traces. At intermediate denaturant concen-
trations, one exponential was sufficient to fit unfolding traces. The kinetic
traces obtained in refolding experiments were also well represented by
a single exponential term.
The observed kinetics of folding and unfolding versus GuHCl concentra-
tion was fitted to a kinetic model based on assumptions that are standard in
the literature. First, we assume that all reactions are unimolecular. Consis-
tent with this assumption, we detected no systematic dependence of the re-
folding kinetics on protein concentration (see Results). This implies that the
fluorescence signal is a sum of n-1 exponential phases for a kinetic model
with n species. Second, the logarithm of each microscopic rate constant kij
is assumed to vary linearly with denaturant concentration, c
ln kij ¼ ln koij þ

m‡ij=RT

c; (1)
where kij
o is the microscopic rate constant from species i to j in the absence
of denaturant. Third, we assume that, under strongly refolding conditions,the folding rate constants kij are significantly larger than their reverse
unfolding rate constants kji, whereas the opposite is true under strongly
unfolding conditions. This implies that in the unfolding experiments, the
protein is initially ~100% in the native state N; conversely, in the folding
experiments, the protein is initially ~100% in the unfolded state U.
The kinetics of (un)folding as a function of denaturant concentration was
modeled using a general matrix approach (33,34). The elementary rate
constants at a given denaturant concentration (Eq. 1) define a rate matrix,
based on the set of linear differential equations describing a sequential
three-state mechanism. The eigenvalues representing the macroscopic
rate constants (observable rates l1 and l2) and corresponding eigenvectors
were calculated by using a program written in Igor Pro. Using a least-
squares fitting algorithm in combination with manual constraints, the
parameters describing each of the microscopic rate constants (Eq. 1)
were varied in an effort to simultaneously fit the observed refolding/unfold-
ing rates at all denaturant concentrations. The set of kinetic parameters thus
obtained (four rate constants, kij
o, and four kinetic m-values, m‡ij) was used
to generate a family of kinetic traces for refolding and unfolding experi-
ments at different denaturant concentrations, c, defined as follows (Eq. 2):
FðtÞ ¼ A1 expðl1tÞ þ A2 expðl2tÞ þ A3: (2)
Amplitudes Ai were computed from eigenvectors by solving a set of
linear equations for a particular set of initial conditions and fluorescence
values for each state, fN/I/U, defined as
fN=I=U ¼ f0N=I=U þ sN=I=U c; (3)
where f0N/I/U is the relative fluorescence in the absence of denaturant and
sN/I/U is the slope versus denaturant concentration. The intrinsic fluores-cence parameters were optimized by using a least-squares algorithm to fit
a set of folding or unfolding traces to a three-state model.
The kinetic m-values (m‡ij value in Eq. 1) represent the change in the
solvation free energy induced by denaturant (35), and thus provides a quan-
titative measure of the average compactness. For a three-state mechanism,
the compactness of the intermediate state relative to the unfolded state can
be represented by a a value:
aUI ¼ ðm‡UI  m‡IUÞ=ðm‡UI þ m‡IN  m‡NI  m‡IUÞ; (4)
where aUI¼ 0 represents an intermediate state with the same surface-burial
as the unfolded state, whereas aUI ¼ 1 represents an intermediate state that
is as compact as the native state.RESULTS
Tryptophan fluorescence reporter
The kinetics of folding and unfolding of ovPrP variants was
monitored by tryptophan fluorescence. The only tryptophan
in the 94-233 fragment of the wild-type ovPrP, Trp-102, is
located in the unstructured N-terminal segment and is
exposed to the solvent under both native and denaturing
conditions. As in previous work with human PrP (29,36),
we prepared a double mutant of ovPrP, W102F/Y221W,
which replaces the endogenous Trp with a conformationally
sensitive fluorescence reporter (Fig. 1). Under native condi-
tions the fluorescence emission of Trp-221 is blue-shifted
and partially quenched, and shows a 4–6-fold increase in
the quantum yield upon unfolding. The secondary structure
of native ovPrP and its double mutant W102F/Y221W was
assessed by circular dichroism; both spectra exhibit a double
minimum at around 208 and 222 nm, which is typical for
a a-helical protein (data not shown). Equilibrium unfold-
ing experiments monitored at pH 5 by far-UV circular
dichroism and fluorescence indicates that the double mutant
has native-like stability. Sedimentation equilibrium experi-
ments were carried out on the ARQ variant of ovPrP using
a Beckman XLI analytical ultracentrifuge at 15,000 rpm,
25C. After 5 days, the sedimentation data (Fig. S2) con-
verged to a classic Boltzmann distribution with an estimated
molecular mass of 17 kDa, in close agreement with pre-
dicted molecular mass of ovPrP94-233 (16.9 kDa).Kinetics of (un)folding reactions on the
submillisecond timescale
A continuous-flow mixing technique (31) was used to
monitor the changes in tryptophan emission (>324 nm)
associated with folding and unfolding of ovPrP variants at
15C as a function of GuHCl concentration (in 50 mM imid-
azole buffer at pH 7.0). Fig. 2, A and B, show representative
refolding traces for the ARQ and ARR, measured after rapid
dilution of the unfolded protein (typically in 5 M GuHCl) to
final GuHCl concentrations in the range of ~0.8–2.4 M.
Each trace is well described by a single exponential decay
(Fig. S3).
To determine if the folding behavior of ovPrP changes
with solution conditions, we measured the kinetics of
refolding of the ARQ, ARR, VRQ, and AHQ variants under
several alternative solution conditions, including different
temperatures (5 and 15C), pH values (5 and 7,) and dena-
turants (GuHCl and urea; see Fig. S4 and Fig. S5). All ovPrP
variants exhibit only one refolding phase under these condi-
tions, indicating that there is no detectable intermediate
under refolding conditions.
Fig. 2, C and D, show a series of unfolding traces for
the ARQ and ARR variants under matching conditions
(pH 7, 15C), measured in continuous-flow fluorescence
experiments involving rapid jumps from native conditionsBiophysical Journal 101(5) 1221–1230
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FIGURE 2 Continuous-flow fluorescence analysis of the kinetic mechanism of folding/unfolding of ovPrP variants ARQ (left panels) and ARR (right
panels). The kinetics of folding (A and B) and unfolding (C and D) was measured in the presence of various concentrations of GuHCl at pH 7, 15C.
Refolding (resp. unfolding) traces were initially normalized relative to the fluorescence profiles of the unfolded protein in 5 M GuHCl (resp. native protein
in 1.8 M GuHCl). Unfolding traces were then divided by the average signal of the unfolded protein in 5 M GuHCl. Solid lines were obtained by nonlinear
least-squares fitting of individual traces, using a single exponential for all experiments up to 4.4 M GuHCl and a sum of two exponentials for unfolding
experiments at 4.8 M GuHCl and above. In panels E and F, the logarithm of the observable rate constants are plotted versus GuHCl concentrations.
Solid lines in panels E and F represent the two observable rates of folding/unfolding predicted by global analysis of the kinetic data for each variant using
a sequential three-state mechanism (U4 I4 N), and dashed lines indicate the corresponding elementary rate constants.
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FIGURE 3 Representative continuous-flow traces illustrating the com-
plex kinetics of unfolding. Solid circles (red) show the time course of
unfolding for the ARQ variant at 5.2 M GuHCl (A) and 5.6 M GuHCl
(B). Solid lines indicate single- and double-exponential fits and the
corresponding residuals (upper: double-exp.; lower: single-exp.). For
Sheep PrP Unfolding Kinetics and Scrapie Susceptibility 1225(1.8 M GuHCl) to denaturing concentrations of GuHCl
(4–6 M). To obtain a satisfactory fit of the unfolding traces
for both variants at high denaturant concentration, it was
necessary to use a sum of two exponentials. This is illus-
trated by Fig. 3, which shows that double-exponential fits
have substantially smaller, more random, residuals than
single-exponential fits. Comparison of the residuals in Table
S2 shows that the deviations from single-exponential
behavior during unfolding become more pronounced with
increasing GuHCl concentration. To rule out the possibility
that these deviations reflect mixing artifacts, we performed
a series of experiments on a strictly exponential test reaction
(oxidation of the indole ring of NAT by NBS) under various
solution conditions, using glycerol to match the viscosity
changes encountered in GuHCl-induced unfolding experi-
ments (Fig. S1). A representative trace is shown in Fig. 3
C; the quality of the fit using a single exponential is excel-
lent with random residuals down to the ~40 ms dead time
(c2¼ 9$104). In contrast, the residuals for single-exponen-
tial fits to unfolding traces (Fig. 3, A and B) are much larger
and dominated by nonrandom components, confirming that
the biphasic nature of the traces reflects complexities in the
kinetics of unfolding rather than instrumental artifacts.
Fig. 2, E and F, show logarithmic (chevron) plots versus
GuHCl concentration for all observable rate constants,
including those of the slow and fast unfolding phases (lslow
and lfast) as well as the single folding phase, which merges
with the slow unfolding phase in the transition region. The
solid lines represent a simultaneous fit of both observable
rate constants obtained by numerically solving the equations
describing a sequential three-state folding mechanism, as
detailed in Materials and Methods. The parameters defining
the denaturant-dependence of the corresponding elementary
rate constants for each transition (dashed lines) are listed in
Table 1.
To determine whether our observations are affected by
protein association, we measured refolding of the ARR
variant at different protein concentrations ranging from
3.2 to 13.5 mM (at a final GuHCl concentration of ~0.8–
1.6 M). There was no systematic variation in rates or ampli-
tudes as a function of protein concentration over this range,
suggesting that the observed folding kinetics reflects the
behavior of monomeric ovPrP, although formally we cannot
exclude the possibility that the concentration required for
multimeric ovPrP dissociation is lower than 3.2 mM.comparison, panel C shows a representative trace for pseudo first-order
(exponential) test reaction in which NATwas mixed with 8 mM NBS under
solvent conditions matching those of the protein unfolding experiment in
5.6 M GuHCl (see text and Fig. S2). All residuals are plotted on the
same scale (50.02) to allow direct comparison of the quality of single-
versus double-exponential fits.Kinetic modeling
Several factors might account for the unusual observation of
single-exponential kinetics during refolding despite the
presence of an intermediate deduced from the more complex
time-course of unfolding, including i), the intermediate is
poorly populated under refolding conditions; ii), the second
refolding phase occurs too fast to be observed; and iii), the
second refolding phase has negligible amplitude. In an effortto discriminate between these possibilities, we used the
kinetic parameters derived by fitting a three-state model to
the chevron plots (Fig. 2 E and F) to predict the family of
kinetic traces as a function of GuHCl concentration (solidBiophysical Journal 101(5) 1221–1230
TABLE 1 Kinetic parameters for the three-state folding
reaction of ovPrP variants*
kUI
0 kIU
0 kIN
0 kNI
0 fU
ARQ 8500 4100 19,000 28 0.83
ARR 5700 6100 65,000 190 0.76
m‡UI m
‡
IU m
‡
IN m
‡
NI fI
ARQ 0.23 0.04 0.29 0.54 0.40
ARR 0.20 0.02 0.38 0.37 0.52
DGUI DGIN DGUN aUI fN
ARQ 0.42 3.72 4.1 0.25 0.40
ARR 0.05 3.33 3.4 0.23 0.52
*Kinetics of folding/unfolding at pH 7, 15C, was analyzed using the mech-
anism U 4 I 4 N. Elementary rate constants kij are in s
1, mij is in
kcal$mol1$M1, and DG is in kcal$mol1 (1 kcal ¼ 4.18 kJ). The last
column lists the intrinsic fluorescence values of U (fU), I (fI), and N (fN),
normalized relative to the signal of the U-state at 5 M GuHCl, obtained
by global fitting of the family of folding and unfolding (a slope of
0.04 M1 was used to account for the denaturant-dependence of the fluores-
cence of each state).
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FIGURE 4 Predicted populations and free energy profiles obtained by
three-state analysis of kinetic data for the ARQ (A and C) and ARR
(B andD) variants of ovPrP. In panels A and B, the elementary rate constants
in Table 1 were used to compute the equilibrium population (solid lines)
and maximum level of transient accumulation of the I-state on a 100-ms
time (dashed lines). The free energy profiles in panels C and D were calcu-
lated using the Arrhenius relationship, assuming a preexponential factor of
1  106 s1. Panel E compares the free energy profiles for three-state
folding of the ARQ (solid) and ARR (dashed) variants in the absence of
denaturant.
1226 Chen et al.lines in Fig. S6). We were able to simultaneously fit all of
the observed folding and unfolding traces for a given variant
with a fixed set of rate parameters (Table 1) after least-
squares optimization of the relative fluorescence amplitudes
of U, I, and N states (fU, fI, and fN) and their dependence on
denaturant concentration (assumed to be linear). Using the
ARQ variant as an example, a preliminary analysis of indi-
vidual folding/unfolding traces at different GuHCl concen-
trations gave values of fU ¼ 0.83 5 0.03 and fI ~ fN ¼
0.40 5 0.015, assuming a constant value of 0.04 for the
slope versus GuHCl concentration (the results for ARR
were similar; see Table 1). Thus, after allowing for a small
amount (<4%) of instrumental variation between individual
experiments, we can simultaneously fit the kinetic data
using a common set of global kinetic parameters and consis-
tent optical properties for the three states. Our ability to
simultaneously fit the raw kinetic traces (Fig. S6) and the
empirically determined chevron plots (Fig. 2, E and F)
confirms the validity of the kinetic model and provides
further confidence in the derived elementary rate parameters
(our kinetic modeling procedures involving a combination
of least-squares and manual optimization does not lend itself
readily to quantitative error estimation).
Because the I- and N-states are indistinguishable in terms
of their fluorescence properties accounts for the absence of
a fast transient in refolding experiments and the observation
of an apparent lag phase in unfolding (reflecting the delay in
the appearance of the U-state due to transient accumulation
of I). Although our kinetic evidence for accumulation of an
intermediate is based on the unfolding data, the elementary
rate constants we obtained by fitting the data to a three-state
model (Table 1) predict that the I-state also accumulates
under refolding conditions (reaching amaximum at a folding
time of ~200 ms; data not shown) and maintains substantial
equilibrium population near the midpoint of the unfolding
transition. This is illustrated in Fig. 4 (panels A and B),
which shows plots of the equilibrium population (solidBiophysical Journal 101(5) 1221–1230lines) and maximal transient population of the I-state
(dashed lines) versus GuHCl concentration, calculated on
the basis of the kinetic parameters in Table 1. Interestingly,
the predicted transient accumulation of the I-state during
folding is substantially higher for the ARQ variant (~21%)
than the ARR variant (6.5%). This conclusion is consistent
with the statistical analysis of the kinetic traces (Table S2),
which reveals more pronounced deviations from single-
exponential behavior during unfolding of the ARQ variant
compared to ARR. The ARQ variant also shows a somewhat
higher population of I at equilibrium (16.7%) compared to
the ARR variant (12.9%). The free energy profiles in
Fig. 4 (panels C and D) illustrate the effect of denaturant
on the relative populations of the three states. Comparison
of the profiles for the two variants in the absence of dena-
turant (Fig. 4 E) explains the difference in I-state population
in terms of a lower barrier for the U/ I transition (TS1),
deeper I-state well, and higher I / N barrier (TS2) for
the ARQ variant compared to ARR. TS1 is the dominant
barrier during folding of ARR, and lslow approaches kUI at
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case of ARQ the two barriers are more similar in height,
and both transitions contribute to the observed folding
rate, lslow, which falls below kUI and decreases sharply
with increasing GuHCl concentration (Fig. 2 E).DISCUSSION
The goal of this study was to identify any intermediate
conformational state(s) that occur during folding and
unfolding of the monomeric ovPrPC to understand their
potential role as precursors for the formation of pathogenic
isoform, PrPSc. It is generally thought that the subunits of
PrPSc are highly ordered, but structurally quite distinct
from PrPC (37–39). The (monomeric) precursor to PrPSc is
likely to be a transient state with a partially unfolded and/or
nonnative structure predisposed to interact with PrPSc
particles. Thus, elucidating the structural and energetic
properties of partially ordered conformational states occur-
ring during unimolecular folding may be critical for under-
standing the PrPC-to-PrPSc conversion. Two factors should
contribute to the rate of PrPSc formation: the population of
the monomeric precursor and its propensity to adopt the
PrPSc conformation. On the basis of these considerations,
we hypothesized that geneticmodulations in classical scrapie
determine either the population or structural properties
(or both) of the precursor state to modulate the propensity
of PrPC to adopt the PrPSc conformation, which has been
observed to correlate with disease susceptibility (23,24).Kinetic intermediate is a plausible PrPSc
precursor
In this study we observed that the population of the I-state
during folding of the susceptible ARQ variant is about three
times higher than that of the resistant ARR variant (Fig. 4).
Our observation that the ARQ and ARR variants have
similar aUI-values (0.25 and 0.23, respectively; Table 1)
suggests that their intermediates are structurally similar; in
each case the I-state buries ~1/4th of the solvent accessible
surface area associated with refolding. On the basis of these
observations, we argue that I is a likely precursor of PrPSc,
and that the genetic modulation in classical scrapie exerts its
effect primarily via the population of this kinetic species
rather than its structural properties.
We propose the following model of amyloid formation in
classical scrapie:
Conformational folding of PrPC: N4 I4 U
Assembly of PrPSc oligomers: (PrPSc)nþ I/ (PrPSc)nþ1
The rate of adding a subunit to (PrPSc)n is a function of the
concentration of the monomeric I-state in solution as well as
that of the preexisting PrPSc seed. Thus, variants with well-
populated I-states are predicted to be more susceptible to
scrapie, and those with poorly populated intermediates areexpected to be resistant. Exogenous PrPSc is required for
the PrPC-to-PrPSc conversion, since naturally occurring
allelic variants of ovPrP, including those that confer high
susceptibility to classical scrapie, do not induce the disease
spontaneously (40,41).Sequential versus parallel folding mechanisms
A kinetic model with parallel pathways is often seen in
protein refolding due to heterogeneity in the unfolded state,
e.g., different isomers of an X-Pro peptide bond (42).
However, parallel pathways are less likely to occur in
protein unfolding, because the native protein population is
generally more homogeneous than the U-state. Indeed, our
kinetic simulations show that a three-state mechanism
with an obligatory intermediate encountered in both folding
and unfolding transitions quantitatively accounts for all
experimental data (Fig. 2). The observation of a lag phase
further supports our conclusion that the I-state is an obliga-
tory intermediate (43,44). However, a rigorous distinction
between these alternative folding models can be made
only in rare cases (43,45), and we have not fully explored
all possible alternatives (such as triangular schemes) in
this study. Nevertheless, the I-state in ovPrP is a strong
candidate for an on-pathway intermediate, because the
two observable unfolding phases converge at high dena-
turant concentration, resulting in tight kinetic coupling,
which is a key requirement for distinguishing alternative
mechanisms (34).Arguments against a native-state precursor
It has been suggested that native PrPC may act as a precursor
to PrPSc under physiological conditions. Zhang et al. (46)
proposed that Syrian hamster PrPC possesses a relatively
open conformation, which is ready for the PrPC to PrPSc
conversion. Welker et al. (47) suggested that oligomeriza-
tion may proceed through a thiol/disulfide exchange reac-
tion between two native PrP molecules. Although such
a dimeric structure has been observed (48), a later report
on in vitro conversion argued against this model (49). Direct
conversion of the native PrPC structure into PrPSc is also
inconsistent with the observation that mutants of human
PrP (huPrP) linked to prion diseases do not differ signifi-
cantly from the wild-type in terms of thermodynamic
stability (50–52). In the case of classical scrapie, susceptible
alleles even exhibit higher structural stability of their native
forms as compared to the resistant ones (26,27). Moreover,
pathogenic or protective mutations associated with human
or sheep prion diseases do not alter the structure or back-
bone dynamics of the native state (52,53). Taken together,
these studies suggest that genetic modulations associated
with prion diseases do not exert their effects on the native
form. On the other hand, mutations can strongly modulate
the structure, stability, and kinetics of formation/decay ofBiophysical Journal 101(5) 1221–1230
1228 Chen et al.folding intermediates (54,55), which therefore are more
plausible PrPSc precursor states.Species difference in the folding kinetics of ovPrP
At low denaturant concentration the ovPrP variants we
studied here refold in a single phase with a time constant
of ~100–300 ms, without resolvable kinetic intermediates.
In contrast, in a previous kinetic study of huPrP at 5C, an
early intermediate was found to accumulate with a time
constant of ~50 ms during refolding from the urea-denatured
state at pH 4.8 and 7, followed by a rate-determining folding
step with a time constant of ~700 ms (29). Instrumentation
plays no role when comparing the present data with the
previous huPrP study (29), because the same capillary mix-
ing system was used for both experiments, although with
improved detector sensitivity in the current study.
Our quantitative kinetic analysis of the combined folding
and unfolding data for the ARQ and ARR variants of ovPrP
(Fig. 2) shows that an intermediate accumulates over a wide
range of denaturant concentrations, but is not observable in
refolding experiments because its fluorescence properties
are indistinguishable from those of the N-state. Thus, the
apparent differences in kinetic behavior are in part due to
species-dependent variation in the properties of the optical
probe used to monitor the reaction. In addition, the free
energy profiles for ovPrP (Fig. 4) show that, in contrast to
huPrP (29), the first barrier encountered (TS1) is rate-
limiting during refolding in the absence of denaturant,
whereas the second barrier (TS2) becomes rate-limiting at
intermediate and high GuHCl concentrations. Thus, rela-
tively small changes in the folding free-energy landscape
can account for qualitative differences in kinetic mecha-
nisms. It is likely that the differences in energetic, kinetic,
and optical properties of the sheep versus human proteins
reflect structural differences in their respective intermedi-
ates. Such species differences have been observed for the
intermediate in human and Syrian hamster PrP (56).Structural correlations in PrPSc formation
The PrPSc conformation has been modeled in terms of
b-helical and spiral structures where much of the native
structure is conserved during the PrPC-to-PrPSc conversion
(37,38). Such structural conservation has been observed in
an antibody study, in which a-helices 2 and 3 in PrPC remain
largely conserved in PrPSc (57). If the interactions in PrPSc
mimicked those in PrPC, i.e., if PrPSc has a native-like struc-
ture, a kinetic species that retains more native interactions
would exhibit higher propensity to convert to PrPSc.
Therefore, these structural models suggest that a partially
unfolded folding intermediate is a more plausible PrPSc
precursor, as compared to the native and unfolded states,
since it retains native-like structure (58), but is flexible to
undergo conversion. An alternative mechanisms involvingBiophysical Journal 101(5) 1221–1230refolding of the entire a-helical domain in the transition
from PrPC to PrPSc has also been proposed (39,59). In this
case, a weakly structured species would be a more plausible
PrPSc precursor, which is consistent with the relatively low
degree of desolvation of the I-state, based on the aUI we
observed (Table 1). However, the precise relation of the
structural properties of I to the PrPC-to-PrPSc conversion
cannot be determined in the absence of a high-resolution
structural model of PrPSc.CONCLUSIONS
We conclude that the structural intermediate, I, observed in
our kinetic studies on ovPrP is a likely candidate as a
precursor in its conversion from the monomeric cellular
form to scrapie particles. The level to which the I-state accu-
mulates transiently and/or at equilibrium is a key factor in
determining the efficiency of conversion. This argument is
based on the observed correlation between the scrapie
susceptibility of the ARQ and ARR variants and I-state pop-
ulation. The higher population of I in the susceptible variant
would strongly favor oligomerization. Such a correlation
has been observed in human familial prion disease, where
pathogenic mutations result in a pronounced increase in
the population and hydrophobicity of a kinetic intermediate
of human PrP (29). Differences between the folding kinetics
of the sheep PrP variants studied here and those reported
previously for the human protein (29) can be explained
by their distinct optical properties together with (subtle)
structural and kinetic differences involving the respective
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